Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132839 | 0.84 | CYP2C9 (0.49) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL2133980 | 0.84 | KMT2A (0.46) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL2464914 | 0.83 | RAB9A (0.51) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL15551965 | 0.80 | HDAC1 (0.43) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL2857931 | 0.72 | MAPT (0.64) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL3773374 | 0.72 | TDP1 (0.49) | RAB9AMEN1KMT2AALDH1A1HDAC1 | |
| SCHEMBL1780463 | 0.71 | MAPT (0.43) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL9674 | 0.70 | MAPT (0.81) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL2138082 | 0.70 | HDAC1 (0.61) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL22461361 | 0.70 | NAMPT (0.61) | RAB9AMAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | HDAC2, HDAC1, HDAC3 | RAB9A 2199/4885MAPT 1265/4885KDM4E 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.